$131.19 Million in Sales Expected for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) This Quarter

Wall Street brokerages forecast that ACADIA Pharmaceuticals Inc. (NASDAQ:ACADGet Rating) will announce sales of $131.19 million for the current quarter, according to Zacks. Eight analysts have provided estimates for ACADIA Pharmaceuticals’ earnings. The lowest sales estimate is $126.00 million and the highest is $135.50 million. ACADIA Pharmaceuticals reported sales of $115.22 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 13.9%. The company is scheduled to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that ACADIA Pharmaceuticals will report full year sales of $530.64 million for the current financial year, with estimates ranging from $512.60 million to $544.91 million. For the next fiscal year, analysts anticipate that the company will report sales of $698.46 million, with estimates ranging from $602.30 million to $778.18 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals (NASDAQ:ACADGet Rating) last posted its earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.21). ACADIA Pharmaceuticals had a negative net margin of 43.50% and a negative return on equity of 40.52%. The firm had revenue of $115.47 million during the quarter, compared to the consensus estimate of $122.22 million. During the same quarter last year, the firm posted ($0.42) EPS. The business’s revenue was up 8.4% on a year-over-year basis.

A number of analysts recently weighed in on ACAD shares. The Goldman Sachs Group lowered their price target on shares of ACADIA Pharmaceuticals from $27.00 to $24.00 and set a “neutral” rating for the company in a report on Monday, March 7th. JMP Securities lowered their target price on shares of ACADIA Pharmaceuticals from $42.00 to $35.00 and set a “market outperform” rating for the company in a report on Tuesday, March 1st. Zacks Investment Research raised shares of ACADIA Pharmaceuticals from a “sell” rating to a “hold” rating and set a $28.00 target price for the company in a report on Wednesday, March 23rd. StockNews.com assumed coverage on shares of ACADIA Pharmaceuticals in a report on Thursday, March 31st. They set a “hold” rating for the company. Finally, Canaccord Genuity Group raised shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their target price for the stock from $30.00 to $31.00 in a report on Wednesday, March 16th. Eleven research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, ACADIA Pharmaceuticals has an average rating of “Hold” and a consensus target price of $29.41.

In other ACADIA Pharmaceuticals news, insider James Kihara sold 1,025 shares of the stock in a transaction that occurred on Friday, April 8th. The shares were sold at an average price of $27.05, for a total transaction of $27,726.25. Following the transaction, the insider now owns 2,433 shares in the company, valued at approximately $65,812.65. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, President Srdjan R. Stankovic sold 2,865 shares of the stock in a transaction that occurred on Monday, May 2nd. The stock was sold at an average price of $18.18, for a total transaction of $52,085.70. Following the transaction, the president now owns 55,188 shares in the company, valued at approximately $1,003,317.84. The disclosure for this sale can be found here. In the last quarter, insiders sold 10,819 shares of company stock worth $205,781. 28.50% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. lifted its position in shares of ACADIA Pharmaceuticals by 8.7% during the fourth quarter. Russell Investments Group Ltd. now owns 138,950 shares of the biopharmaceutical company’s stock valued at $3,241,000 after purchasing an additional 11,172 shares in the last quarter. Rockefeller Capital Management L.P. lifted its position in shares of ACADIA Pharmaceuticals by 21.4% during the third quarter. Rockefeller Capital Management L.P. now owns 281,228 shares of the biopharmaceutical company’s stock valued at $4,671,000 after purchasing an additional 49,644 shares in the last quarter. Advisor Group Holdings Inc. lifted its position in shares of ACADIA Pharmaceuticals by 10.0% during the fourth quarter. Advisor Group Holdings Inc. now owns 26,485 shares of the biopharmaceutical company’s stock valued at $623,000 after purchasing an additional 2,399 shares in the last quarter. First Quadrant L P CA lifted its position in shares of ACADIA Pharmaceuticals by 37.5% during the fourth quarter. First Quadrant L P CA now owns 16,500 shares of the biopharmaceutical company’s stock valued at $385,000 after purchasing an additional 4,500 shares in the last quarter. Finally, Bioimpact Capital LLC bought a new position in shares of ACADIA Pharmaceuticals during the fourth quarter valued at about $2,918,000. Institutional investors own 91.74% of the company’s stock.

NASDAQ:ACAD opened at $17.08 on Monday. The stock has a market capitalization of $2.76 billion, a P/E ratio of -12.84 and a beta of 0.67. The firm has a 50 day moving average of $21.07 and a 200-day moving average of $22.38. ACADIA Pharmaceuticals has a 1 year low of $15.16 and a 1 year high of $28.06.

About ACADIA Pharmaceuticals (Get Rating)

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Read More

Get a free copy of the Zacks research report on ACADIA Pharmaceuticals (ACAD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.